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AIMS AND OBJECTIVE 
 
1. To determine the prevalence of undiagnosed type 2 
diabetes mellitus and impaired glucose tolerance 
in newly diagnosed patients with uncomplicated 
essential hypertension. 
 
2. To determine the prevalence of abnormal lipid 
profile in patients with uncomplicated essential 
hypertension in relation to age and sex. 
 
3. To determine the prevalence of metabolic syndrome 
in patients with essential hypertension. 
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INTRODUCTION 
 
  Hypertension is an emerging health problem in India.  
It is a cardinal risk factor for coronary artery disease (CAD) 
and the risk of CAD further increases in presence of 
dyslipidemia.  Both hypertension and dyslipidemia coexist 
more often than by chance alone.1 
  The Diabetes Atlas published by the International 
Diabetes Federation  shows that India currently leads the 
world in number of people with diabetes and is currently 
home to over 40 million diabetics and is predicted to 
increase to 69 million  by 2025.  Further  India occupies the 
second position with number of subjects with Impaired 
Glucose Tolerance (IGT).2  
  Insulin resistance and hyperinsulinemia are 
considered as pathogenetic factor in both hypertension and 
dyslipidemia, both by themselves are risk factors for 
Coronary Artery Disease. 
  The co-existence of hypertension dyslipidemia and 
diabetes mellitus substantially increases the risk of macro 
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vascular complications, including stroke, coronary disease 
and is responsible for increased cardio vascular mortality. 
 
  Thus, it becomes essential to screen the patients with 
essential hypertension for lipid abnormalities and impaired 
glucose tolerance. 
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REVIEW OF LITERATURE 
 
HYPERTENSION: 
Definition:3 
  Clinically, hypertension might be defined as  Systolic 
blood pressure ≥ 140 mm Hg and diastolic blood pressure   
≥ 90mm Hg based on average of two or more readings. A 
single reading is sufficient if systolic BP is ≥  210 mm Hg or 
diastolic BP ≥ 120 mmHg. 
                                                                                                         
JNC VII classification 3 
Blood pressure classification for aduts aged 18 years 
and older 
                      Systolic BP( mm Hg) Diastolic BP (mmHg) 
Normal             < 120       and  < 80 
Pre hypertension      120-139    or 80-89 
Stage 1 hypertension 140-159    or 90-99 
Stage 2 hypertension ≥ 160     or ≥ 100 
* Isolated systolic hypertension is defined as systolic BP ≥ 
140 mmHg and diastolic BP ≥   90 mmHg and staged 
appropriately. 
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FACTORS AFFECTING BLOOD PRESSURE 
Smoking:  
  Smoking causes an increase in both Systolic BP and 
Diastolic BP lasting for about 30 minutes. 
Caffeine: 
  It causes an increase in BP by increasing both renin 
and catecholamines levels.   
Alcohol: 
  Modest consumption of alcohol (< 30 g of ethanol a 
day) is generally not associated with increase in BP. Larger 
amounts of alcohol ingestion have a dose related effect on 
BP both in  hypertensives and normotensive subjects.4 
Genetic determinants: 
         Concordance of blood pressures is higher in families 
than in unrelated individuals , higher between monozygoyic 
than dizygotic twins. 
 
Salt intake: 
         Excess sodium intake increases BP by increasing fluid 
volume and preload, thereby increasing cardiac 
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output.Chloride and not just sodium may be involved  in  
hypertension.  BP rises  more  with  NaCl  (sodium chloride 
salt) than with nonchloride salts of sodium.5 
 
PSEUDO HYPERTENSION: 
 In some elderly patients with very rigid calcified 
arteries the bladder of the BP apparatus may not be able to 
collapse the brachial artery giving rise to falsely high 
reading or pseudo hypertension (Osler’s sign) 
 
WHITE COAT HYPERTENSION: 6  
  Approximately 15-20% of patients with stage I 
hypertension based on office blood pressures have average 
ambulatory readings < 135/85 mm Hg.  This phenomenon 
called " White coat hypertension” may also be associated 
with an increased risk of target organ damage.  These 
individuals are also at increased risk for developing 
sustained hypertension. 
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AMBULATORY BP MONITORING: 6, 8 
  Home blood pressure and average 24 hour ambulating 
blood pressure measurements are generally lower than 
clinic blood pressures.  Because ambulatory blood pressure 
recordings yield multiple readings throughout the day and 
night, they provide a more  comprehensive assessment of 
the vascular burden of hypertension than a limited number 
of office readings.  They also more reliably predict target 
organ damage than office blood pressures. 
 
Technical Advantages of ABPM vs Clinic BP 
measurement 
Twenty-four hours average BP values are more reproducible 
than isolated office recordings. 
 ABPM does not prevent the occurrence of 
physiological nocturnal BP variations. 
 ABPM does not trigger any alerting reaction and 
pressure rise in the patients; and therefore avoids 
the " white coat effect ". 
 ABPM is also largely unaffected by any placebo 
effect. 
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Indications for ABPM 
The following are the situations in which ABPM may be 
useful: 
 Office or white coat hypertension 
 Evaluation of drug resistance / drug trials for 
effective control of BP 
 Evaluation of nocturnal BP changes 
 Episodic hypertension 
 Hypertensive symptoms associated with 
antihypertensive medication or automatic 
dysfunction 
 Carotid sinus syncope and pacemaker syndromes 
 Hypertension in pregnancy 
 Hypertension in children and adolescents. 
           
Day Vs Night BP: 8 
  Night time blood pressures are generally 10 - 20% 
lower than day time blood pressure.  Investigators have 
defined hypertensive patients as ‘dippers’ or ‘non dippers’ 
based on the reduction of night time BP, respectively greater 
or smaller than 10% as compared to day time values. An 
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attenuated night time blood pressure "dip"  is associated 
with increased cardiovascular disease risk. 
 
  Blunting of day night blood pressure pattern occurs in 
several conditions like sleep apnea, autonomic neuropathy 
and in certain population  including African Americans 
diabetes, obesity and renal insufficiency.7,8 
  
 Recommended criteria for a diagnosis of hypertension 
by this method are awake blood pressure ≥ 135/85 mm Hg 
and asleep blood pressure ≥ 120/75 mm Hg.  These levels 
approximate a clinic blood pressure of 140/90 mm Hg 6 
 
HYPERTENSIVE CRISIS: 
         Includes hypertensive urgencies and emergencies. 
          Hypertensive urgencies are defined as a  
substantial increase in BP  usually with a diastolic BP of 
120-130  mmHg   (including upper levels of stage 2 
hypertension , optic disc edema , progressive end organ 
complications rather than damage  and severe perioperative 
hypertension ) warranting BP reduction within hours.3 
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        Hypertensive Emergencies –include accelerated 
hypertension- defined as systolic BP > 210 and diastolic BP 
> 130 mmHg presenting with headache, blurred vision or  
focal neurological deficits, and malignant hypertension  
which requires the presence of papilledema.9 
 
CAUSES OF HYPERTENSION :6 
ESSENTIAL HYPERTENSION:  
 80 – 95% of hypertensive patients are diagnosed as 
having essential hypertension also referred to as primary or 
idiopathic hypertension.  In the remaining 5 – 20 % a 
specific underlying  disorder causing elevation of BP is 
identified. 
SECONDARY HYPERTENSION 
  In individuals with secondary hypertension ,a specific 
mechanism for the blood pressure elevation is often 
apparent. 
Systolic hypertension with wide pulse pressure: 
1. Decreased vascular compliance (arteriosclerosis) 
2. Increased cardiac output. 
(a) Aortic  regurgitation 
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(b) Thyrotoxicosis 
(c) Hyperkinetic  heart syndrome 
(d) Arteriovenous fistula 
(e) Patent ductus arteriosus 
Systolic and diastolic hypertension 
1. Renal  
 A. Parenchymal renal disease 
 B. Polycystic kidney disease 
 C. Renin producing tumors 
 D. Obstructive uropathy 
2. Renovascular :  Arterio sclerotic 
       Fibromuscular dysplasia 
3.Adrenal : 
   Primary aldosteronism 
    Cushing’s syndrome 
    17 α hydroxylase deficiency 
    11 β hydroxylase deficiency 
    11 hydroxy steroid dehydrogenase deficiency 
    Pheochromocytoma. 
4. Coarctation of aorta 
5. Obstructive sleep apnea 
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6. Pre eclampsia / eclampsia 
7. Neurogenic :  
Psychogenic 
    Diencephalic syndrome 
    Familial  dysautonomia 
    Polyneuritic  (acute porphyria,  lead poisoning) 
    Increased intracranial pressure 
    Acute spinal cord section 
8. Endocrine –  Hypothyroidism 
Hyperthyroidism 
      Hypercalcemia 
Acromegaly. 
9. Medications -   
High dose estrogens 
                Adrenal steroids 
    Decongestants 
                Appetite suppressants 
    Cyclosporine 
Tricyclic antidepressants 
    Monoamine oxidase inhibitors 
    Erythropoietin 
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Cocaine 
    Non steroidal anti – inflammatory agents 
10. Mendelian forms of hypertension 
 
MECHANISMS OF HYPERTENSION6 
 
DETERMINANTS OF ARTERIAL PRESSURE 
                       Stroke volume 
         Cardiac output       
                        Heart rate 
Arterial pressure         
Vascular  
structure 
       Peripheral resistance     
Vascular 
function 
 
 
1. Intravascular volume 
 Blood flow = Pressure across the vascular bed 
         Vascular resistance 
  When NaCl intake exceeds the capacity of the kidneys 
to excrete sodium, vascular volume initially expands and 
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cardiac output increases.  However overtime,  peripheral 
resistance increases and cardiac output reverts to normal. 
 As arterial pressure increases in response to high NaCl 
intake,  urinary sodium excretion increases and sodium 
balance is maintained at the expense of an increase of an 
increase in arterial pressure, a phenomenon called " 
pressure – natriuresis ". 
 
2. Autonomic nervous system 
  Norepinephrine , epinephrine and dopamine are the 
three endogenous catecholamines  acting  through  α  and  
β   receptors .  α  receptors are more activated by 
norepinephrine(NE) than by epinephrine and the reverse is 
true for β receptors . α1 receptors located on post synaptic 
cells in smooth muscle elicit vasoconstriction .α2 receptors 
localized on presynaptic membranes of post  ganglionic 
nerve terminals that synthesize norepinephrine act as 
negative feed back controllers inhibiting further NE release. 
 
  β1 receptor activation stimulates  cardiac contraction 
and increases cardiac output and stimulates renin release 
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from kidneys. β2 receptor activation by  epinephrine release 
relaxes the vascular smooth muscle cells resulting in 
vasodilatation. 
  Arterial baro reflex modulate blood pressure; mediated 
by stretch sensitive sensory nerve endings located in the 
carotid sinuses and  aortic arch.  As BP increases , 
baroreceptors are stimulated which decreases the 
sympathetic outflow  resulting in decrease of arterial 
pressure and heart rate. 
 
3. Renin Angiotensin Aldosterone system 
         Renin is synthesized by the juxtaglomerular cells.   
There are three primary stimuli for renin secretion 
(1)    Decreased NaCl transport in the thick ascending  
limb of loop of henle   (Macula densa mechanism). 
(2)  Decreased pressure or stretch within the renal 
afferent arteriole (baroreceptor mechanism) 
(3)  Sympathetic nervous system stimulation of renin – 
secreting cells via β1 adreno receptors. 
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Renin Angiotensin – Aldosterone system 
 
               Angiotensinogen 
 Renin 
Angiotensin I                    Bradykinin 
          ACE kininase II 
Angiotensin II                             Inactive 
peptides 
 
AT1 receptor             AT2 receptor 
 
Aldosterone  
  
  Once released into the circulation active renin  cleaves 
angiotensinogen to form an inactive decapeptide, 
angiotensin I.  A converting enzyme, located primarily but 
not exclusively in the pulmonary circulation converts 
angiotensin I to the active octapeptide, angiotensin II.  The 
same enzyme cleaves a number of other peptides including 
bradykinin and thereby inactivating them. 
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  Acting primarily through angiotensin II type I (AT1) 
receptor located on cell membranes, angiotensin II is a 
potent pressor substance, the primary trophic factor for the 
secretion of aldosterone by the adrenal zona glomerulosa, 
and a potent mitogen stimulating vascular smooth muscle 
and myocyte growth. 
 
  An angiotensin II type 2 (AT2) receptor widely 
distributed in the kidneys has opposite effects of AT1 
receptor and induces vasodilation, sodium excretion and 
inhibition of cell growth and matrix formation. 
 
  The renin-angiotensin aldosterone  system contributes 
to arterial pressure primarily via the vasoconstrictor 
properties of angiotensin II and the sodium retaining 
properties of aldosterone. 
4. Vascular mechanisms 
 
  Resistance to flow varies inversely with the fourth 
power of radius.  In hypertensive patients,mechanical, 
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structural and functional changes decrease the  lumen 
diameter of small arteries and arterioles and the peripheral 
vascular resistance increases. 
 
  Activity of Na+ - H+ exchanger is increased in 
hypertension and this may result in increased vascular tone 
by two mechanisms- first, increased sodium entry may lead 
to increased vascular tone by activating Na+ - Ca2+ exchange 
and thereby increasing intra cellular calcium. 
 
  Second,  increased intracellular pH enhances calcium 
sensitivity of the contractile apparatus, leading to an 
increase in contractility for a given intra cellular calcium 
concentration.  Additionally,  increased    Na+ - H+ exchange 
might stimulate vascular smooth-muscle cell growth by 
enhancing sensitivity to mitogens. 
 
  Vascular endothelial function also modulates vascular 
tone.  The vascular endothelium synthesizes and releases 
vasoactive substance including Nitric oxide, a potent 
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vasodilator. Endothelium dependent    vasodilatation is 
impaired in hypertensive patients. 
 
REVIEW OF LITERATURE – DIABETES MELLITUS 
  
 Diabetes mellitus refers to a group of common 
metabolic disorders that share the phenotype of 
hyperglycemia.  The factors contributing to hyperglycemia 
include reduced insulin secretion, decreased glucose 
utilization and increased glucose production. 
 
Criteria for diagnosis of Diabetes:6 
- Symptoms of diabetes plus random blood glucose  ≥  200 
mg/dL 
- Fasting plasma glucose ≥ 126 mg/dL 
- Two hour plasma glucose  ≥  200 mg /d L during an oral 
glucose tolerance test. 
 
Glucose tolerance is classified into three categories based on 
FPG 10 
1. FPG < 100 mg/dl – Normal. 
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2. FPG :100 – 125 mg /dl – Impaired Fasting Glucose 
3. FPG > 126  mg/dl– Diabetes 
 
Based on OGTT , 
IGT is defined as plasma glucose levels between 140 – 
199 mg / dl and diabetes is defined as glucose > 200 mg/dl 
2h after 75g oral glucose load.10 
 
  
Normal 
 
 
Prediabetes 
(IFG/IGT) 
 
Diabetes 
 
FPG (mg/d L) 
 
 
< 100 
 
100 - 125 
 
> 126 
 
2h PG(mg/d L) 
 
< 140 
 
140 - 199 
 
> 200 
 
 
Risk factors for type 2 diabetes mellitus 6 
1. Family history of diabetes 
2. Obesity-BM1 > 25 kg/m2    
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3. Habitual physical inactivity 
4. Race / ethnicity (African Americans, Asian Americans,  
Pacific Islanders) 
5. Previously identified IFG or IGT 
6. History of GDM or delivery of baby > 4Kg 
7. Hypertension (blood pressure ≥ 140/90mm Hg) 
8. HDL – C < 35mg /dl and / or Triglyceride > 250mg/dl 
9. Polycystic ovary syndrome or acanthosis nigricans 
10. History of vascular disease. 
 
Note:  IFG – impaired fasting glucose 
   IGT – impaired glucose tolerance 
   GDM – Gestational diabetes mellitus. 
  Hypertension can accelerate other complications of 
Diabetes, particularly cardiovascular disease and 
nephropathy.  The target goal of BP is < 130/80 mm Hg in 
diabetic individuals without proteinuria and < 125/75 mm 
Hg  in for individuals with micro albuminuria or macro 
albuminuria. 
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Dyslipidemia 
 
  Dyslipidemia is an important risk factor for coronary 
artery disease.The NCEP : ATP III (National Cholesterol 
Education Program : Adult Treatement Panel had published 
guidelines for the diagnosis and evaluation of high blood 
cholesterol in adults 11 
  
The normal lipid profile is defined as : 
LDL –cholesterol <130mg%, total cholesterol <200mg/dl ,    
Triglycerides <150mg/dl .Desirable HDL – C: > 40 mg/dl 
(Males) and > 50 mg/dl (Females). 
 
  The most common pattern of dyslipidemia encountered 
in diabetes is hypertriglyceridemia and reduced HDL 
cholesterol levels.   Diabetes itself does not increase levels of 
LDL, but the small dense LDL particles found in type 2 DM 
are more atherogenic because they are more easily glycated 
and susceptible to oxidation. 
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THE METABOLIC SYNDROME11,12, 13 
 
  It is a constellation of factors including abdominal 
obesity, insulin resistance  or diabetes and atherogenic lipid 
profile. According to the NCEP : ATP III 2001 criteria : 11,12,14  
 Patients are  considered to have the metabolic syndrome 
if they have three or more of the following: 
1. Abdominal obesity : 
 Waist circumference   > 102  cm in men 
                > 88 cm in women 
2. Triglyceride ≥150 mg / dl. 
3. HDL – C   < 40 mg / dl in men and   < 50 mg / dl in 
women 
4. Blood pressure ≥ 130 / 85 mm Hg 
5. Fasting plasma glucose ≥ 100 mg / dl. 
 
METABOLIC SYNDROME AND HYPERTENSION 
   
  Hypertension is seen in 30  - 50% patients with type 2 
DM and 20 – 40% of individuals with IGT:  conversely, 
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about 50% of hypertensives have impaired insulin 
sensitivity.13 
  Hypertension is one of the defining characteristics of 
the metabolic syndrome.  The etiology of hypertension in the 
metabolic syndrome is multifactorial – genetic factors, 
hyperinsulinemia  and obesity. 
  The risk factors for developing metabolic syndrome 
include : obesity, sedentary life style, ageing, diabetes 
mellitus,  coronary heart disease and lipodystrophy. 
  
ROLE OF INSULIN IN THE PATHOGENESIS OF 
ESSENTIAL HYPERTENSION 13 
 
1) Insulin physiologically lowers the blood pressure in 
humans by inducing vasodilatation mediated by 
increased synthesis of nitric oxide . 
 
  Insulin exerts both vasodilator as well as pressor 
effects on vascular beds.  The vasodilator action is mainly in 
skeletal muscles.  Insulin directly stimulated endothelial 
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nitric oxide synthetase (eNOS) activity and releases NO.  
Nitric oxide causes vascular smooth muscle relaxation. 
  Insulin directly stimulates the calcium pump in 
vascular smooth muscle cells,  decreasing the intracellular 
calcium.  In the insulin resistant state, intracellular 
cytosolic calcium is increased; enhancing vascular smooth 
muscle response to vasoconstrictors. 
 
2) Normally insulin release after food intake stimulates 
glucose uptake in the ventromedial thalamus.  This is turn 
increases symphathetic activity and plays an important 
physiological role in dietary thermoregulation. 
 
3)  Insulin also acts in the distal renal tubule causing 
sodium and water retention.  Renal tubular sensitivity to 
insulin is preserved in hyperinsulinemia. In 
hyperinsulinemia there is greater increase in sympathetic 
activity resulting in  hypertension through its effects on 
blood vessels and heart. 
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 4) Insulin may also stimulate proliferation of vascular 
smooth muscle cells, leading to medial hypertrophy and 
increased peripheral vascular resistance. 
 
5) Insulin resistance is characterized by impairment of 
phosphatidyl-  3- kinase signalling pathway causing 
imbalance  between nitric oxide and endothelin – 1 
production.  Enhanced endothelin activity prevents 
vasodilation to insulin in insulin resistance15.  Resistin also 
impairs insulin induced vasodilation16. 
  Thus while insulin normally has a vasodilatory effect, 
hyperinsulinemia in insulin resistant states produces 
hypertension. 
  Several studies prove that decreased sensitivity to 
insulin is involved in the pathogenesis of essential 
hypertension.  The hyperinsulinemia is caused by beta-cell 
hypersecretory response to the defective peripheral action of 
the hormone and by a decreased hepatic insulin  
clearance.17. Essential  hypertension is an insulin resistant 
state and insulin resistance correlates directly with the 
severity of hypertension.18 
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PATHOPHYSIOLOGY OF METABOLIC SYNDROME 
Insulin resistance: 12 
  An early major contributor to the development of 
insulin resistance is over abundance of free fatty acids, 
derived from adipose tissue triglyceride stores released by 
hormone sensitive lipase. 
 
  Fatty acids are also derived through the lipolysis of 
triglyceride – rich lipoproteins in tissues by lipoprotein 
lipase.  Insulin mediates both antilipolysis and the 
stimulation of lipoprotein lipase in adipose tissue. 
 
  The antilipolytic action in adipose tissue is the most 
sensitive pathology of insulin action.  Thus when insulin 
resistance develops, increased  lipolysis produces more fatty 
acids,  which further decrease the antilipolytic effect of 
insulin. Fatty acids impair insulin mediated glucose uptake 
and accumulate as triglycerides in both skeletal and cardiac 
muscle whereas increased glucose production and 
triglyceride  accumulation are seen in liver. 
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  In the oxidative stress hypothesis studies in insulin 
resistant subjects with obesity or type 2 DM, a defect is 
identified in mitochondrial oxidative phosphorylation 
leading to accumulation of triglycerides in muscle which is 
associated with insulin resistance. 
 
  Adipose tissue produces inflammatory cytokines – C-
Reactive protein, interleukin-6 and tumour necrosis factor 
(TNF-α.).  CRP activates complement, decreases NO 
production and increases plasminogen activator 
inhibitor(PAI-1) levels. 
 
  Adiponectin is a cytokine released by adipose tissue 
with insulin sensitizing effects.  Decreased adiponectin 
plays important role in metabolic syndrome. Leptin from 
mature adipocyte binds to hypothalamic receptor and 
induces satiety.  Hypothalamic mediated leptin resistance 
perpetuates a vicious cycle of hyperinsulinemia, more fat, 
more leptin.19 
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CAUSES OF HYPERTENSION IN A PATIENT WITH 
DIABETES20 
  Association 
Cardio metabolic syndrome 
Nephropathy 
 Hypertension and diabetes due to common endocrine 
pathology 
Acromegaly 
Cushing’s syndrome 
Conn’s syndrome 
Pheochromocytoma 
 Drugs inducing both hypertension and diabetes  
Steroids 
Oral contraceptive pills 
 Diabetogenic anti hypertensive drugs 
Diuretics-  chlorthalidone, thiazides 
Β-blockers 
 Chance occurrence of hypertension along with diabetes 
Essential  hypertension 
Isolated systolic hypertension 
Primary renal pathology 
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EFFECTS OF ANTI HYPERTENSIVE AGENTS ON 
GLUCOSE METABOLISM21 
 
Angiotensin converting enzyme inhibitors 
 
  ACEIs are the initial drug of choice for patient who has 
both diabetes and hypertension especially if associated with 
albuminuria.  There is increasing data that ACEIs improve 
insulin sensitivity.  A 34% relative risk reduction for 
developing diabetes was observed in HOPE trial.22 
 
Angiotensin receptor blockers  (ARB) 
  ARBs like ACEIs have shown to reduce the risk of new-
onset diabetes. 
 
Thiazide diuretics23 
  The adverse effects on lipid and carbohydrate 
metabolism are uncommon with low dose thiazide therapy; 
however thiazides should be used judiciously in 
hypertensives with elevated fasting glucose. 
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Calcium channel blockers 
  CCBs have been shown to reduce insulin resistance or 
new onset diabetes in people with cardiometabolic syndrome 
and increase HDL. 
 
β  blockers 
  β blockers have adverse effects on glucose and lipid 
profile and are implicated in new onset diabetes in obese 
patients.  However non selective β blockers like carvidelol 
reduce cardiovascular mortality  and microalbuminuria 
without adversely affecting the glucose or lipid profiles. 
 
  Despite their adverse effects, they have significant 
favourable effects on  cardiovascular disease outcome in 
hypertensive diabetic patients and are included in therapy. 
 
α Antagonists: 
  Selective α1 blockers like prazosin, terazosin lower LDL 
cholesterol, raises HDL cholesterol and improves insulin 
sensitivity.  
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MATERIALS AND METHODS 
 
  This study was carried out with the aim of studying 
the prevalence of impaired glucose metabolism  and 
dyslipidemia among newly detected essential hypertensive 
patients.  The study was conducted in the Hypertension 
clinic, Tirunelveli Medical College Hospital over a period of 6 
months from July 2007 to December 2007. 
 
METHODOLOGY 
 
  Newly diagnosed patients with  hypertension in the out 
patient department and in the hypertension clinic are 
included in this study.  The hypertension was diagnosed 
based on JNC VII criteria, i.e. systolic blood pressure ≥  140 
mm Hg and or diastolic blood pressure ≥ 90 mm of Hg. 
 
  The selected  individuals underwent general physical 
examination to rule out any systemic illness. 
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Study design   : Cross sectional study 
Patient selection : Simple random selection 
SELECTION    
INCLUSION CRITERIA 
1. Patients having blood pressure ≥140 /90 mmHg were 
selected. 
2. Patients with sustained elevation of blood pressure ≥ 
140/90 mmHg on 3 separate occasions were selected. 
3. Patients  of age group ranging from 30 – 70 years were 
included in the study. 
 
EXCLUSION CRITERIA: 
1. Patients with secondary hypertension were excluded. 
2. Patients who are known diabetes were excluded. 
3. Individuals with renal failure, heart disease, stroke, 
liver disease and other systemic illness were excluded 
from the study. 
4. Patients with paroxysms of hypertension were 
excluded. 
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5. Patients with target organ damage like retinopathy,  
nephropathy, cardiovascular disease were excluded. 
6. Patients taking drugs for other illnesses were excluded. 
 
DOCUMENTATION OF BLOOD PRESSURE:7 
  The standard sphygmomanometer with prescribed cuff 
size was used. 
1. The same instrument was used for all the patients 
throughout the study. 
2. Calibration of blood pressure was done frequently to 
ensure the mercury level at zero. 
3. Three readings were taken for a single patient to 
exclude labile hypertension or paroxysmal 
hypertension. 
4. Cuff of proper size was used for the patient. 
5. The centre of the cuff should be at heart level and the 
length & width of the bladder cuff used was 25  x  10 
cm. 
6. The bladder should encircle atleast 80% of the 
circumference and cover two- thirds of the arm. 
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7. Bladder has to be inflated quickly to a pressure 20 
mmHg above the systolic BP , recognized by 
disappearance of radial pulse , to avoid an 
auscultatory gap. 
8. Bladder has to be deflated at 3 mmHg/sec 
9. Korotkoff phase I (appearance) and phase V 
(disappearance) are recorded. 
10. Before taking measurement, the individual was 
seated quietly for 15 min in a quiet room with a 
comfortable room temperature. 
11. Patients were advised to empty bladder, reduce 
anxiety; to avoid exercise,  coffee , tea ,smoking for half 
an hour preceding  the measurement. 
 
BLOOD INVESTIGATIONS: 
• Fasting blood for lipids and blood sugar was collected. 
• Fasting is defined as no caloric intake for at least 8 h. 
• Oral glucose tolerance test was done in all the 50 
patients selected for the study. 
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• The test was performed using a glucose load 
containing the equivalent of 75g anhydrous glucose 
dissolved in water. 
• Two hours later plasma blood glucose was estimated. 
• Venous plasma was taken for the estimation. 
• Blood glucose was estimated by glucose oxidase 
method; the value expressed in mg / dl. 
• The total cholesterol (TC), Triglyceride (TG) and HDL-C 
were measured by enzymatic method. 
• The LDL-Cholesterol was derived by the Friedwald’s 
formula24 
             LDL – C  = TC – ( HDL+TG/5) 
 
Waist circumference:14 
 Is measured at the level of the tip of the right iliac crest 
and measurement is made at the end of expiration. 
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OBSERVATION AND RESULTS 
 
Table 1 
Pattern of distribution of patients with respect to the 
stage of hypertension. 
 
Hypertension No of patients Percent % 
Stage 1 21 42% 
Stage 2 29 58% 
 
Table 2 
Prevalence of undiagnosed diabetes mellitus and 
impaired glucose tolerance in patients with newly 
detected essential hypertension. 
 
 No of patients Percent % 
T2DM 5 10% 
IGT 16 32% 
NGT 29 58% 
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Table 3 
 
Prevalence of impaired glucose metabolism (DM /IGT) in 
newly detected patients with essential hypertension in 
relation to age. 
 
Age in 
years 
No of 
patients 
DM 1GT Normo 
Glycaemia 
No % No % No % 
31-40 8 - 0% 2 25% 6 75% 
41-50 18 2 11.11% 5 27.78% 11 16.11% 
51-60 20 3 15% 7 35% 10 50% 
61-70 4 0 - 2 50% 2 50% 
Total 50 5 10% 16 32% 29 58% 
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Table 4 
 
Prevalence of impaired glucose metabolism (DM +1GT) 
in patients with newly detected essential hypertension 
in  relation to sex. 
 
 
Sex No. of 
patient 
DM 1GT NGT 
No % No % No % 
 
Males 
 
30 
 
3 
 
10% 
 
9 
 
30% 
 
18 
 
60% 
 
Females 
 
20 
 
2 
 
10% 
 
7 
 
35% 
 
11 
 
55% 
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Table 5 
 
Prevalence  and Pattern of Dyslipidemia in patients with 
essential hypertension 
 
 ↑ Total 
cholesterol 
↑ TGL ↓ HDL  
<   40(men)  
< 50(women) 
↑ LDL  
> 130 
No of 
patients 
out of 50 
 
12 
 
16 
 
19 
 
12 
 
Percent 
 
24% 
 
32% 
 
38% 
 
24% 
 
 
↑-increased 
↓-decreased 
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Table 6 
 
Prevalence of dyslipidemia associated with impaired 
glucose metabolism in patients with essential 
hypertension 
 
↑-increased 
↓-decreased 
 No.of  
patients 
With 
dyslipidemia 
Percent 
(%) 
Dyslipidemia 
Associated with IGM/DM 
No. of 
patients 
% out of patients 
with abnormal lipid 
value 
 
↑ TC 
 
12 
 
24% 
 
7 
 
58.8% 
 
↑ TGL 
 
16 
 
32% 
 
9 
 
56.22% 
 
↓ HDL 
 
19 
 
38% 
 
12 
 
63.16% 
 
↑ LDL 
 
12 
 
24% 
 
7 
 
58.3% 
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Table 7 
 
Prevalence of dyslipidemia in patients with essential 
hypertension in relation to sex 
 
 No of 
patients 
Patients 
with 
normal 
lipid 
profile 
Percent Patients 
with 
dyslipidemia 
Percent 
 
Males 
 
30 
 
16 
 
53.33% 
 
14 
 
46.67% 
 
Females 
 
20 
 
7 
 
35% 
 
13 
 
65% 
 
Total 
 
50 
 
23 
 
46% 
 
27 
 
54% 
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DISCUSSION 
 
  In this study, out of the total 50 patients 21 were 
found to be in  stage 1 hypertension  (42% )  and  29 
patients  were  in  stage  2  hypertension  (58 %) (Table 1) 
(Fig 1) 
 
         Out  of  the  50 patients with uncomplicated 
hypertension, 5  patients (10%) had diabetes, 16 patients  
(32%) had impaired glucose tolerance, 29 patients (58%) 
had normal glucose tolerance. 42% of the patients among 
the hypertensives had impaired glucose metabolism, either 
diabetes or impaired glucose tolerance , which was 
previously undiagnosed.(Table 2) (Fig 2) 
 
  The study proves that impaired glucose metabolism is 
common in patients with essential hypertension and  
impaired glucose tolerance (32% ) is more prevalent than 
diabetes (10%) . 
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The results of our study are similar to other studies done 
in the past.  The San Antonio Heart study 25  done in 1993 
showed a prevalence of undiagnosed type 2 diabetes 
mellitus and impaired glucose tolerance to be 8.9% and 
25.2% respectively. 
  
 Johnson et al 26found a prevalence of 11.5% and 41% of 
T2DM and 1GT respectively. In studies in India by Joglekar 
and Nanivadeker 27 36% of patients with essential 
hypertension had impaired glucose metabolism. 
 
In the present study,in patients above 50 years of age 
37.5% had impaired glucose metabolism and 12.5% had 
diabetes.  In hypertensive patients less than 50 years ,the 
values were 26.9% and 7.69% respectively.  Thus the 
prevalence of abnormal glycaemic metabolism is more in 
patients above 50 years of age (Table 3) (Fig 3) 
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  The prevalence of diabetes was equal (10%) in both 
males and females and that of impaired glucose tolerance 
was 30% in males; 35% in female hypertensives (Table 4) 
(Fig 4) 
 
  According to the NCEP / ATP III criteria, the 
prevalence of dyslipidemia was: high cholesterol – 24%, 
hypertriglyceridemia 32% ,low HDL 38%, high LDL 24%  in 
this study .(Table 5).The common forms of dyslipidemia 
noted in our study were low HDL and hypertriglyceridemia . 
 
  7 out of 12 patients (58.8%) with abnormal lipid profile 
had associated impaired glucose metabolism.   9 out of  16 
patients (56.22%) with raised TG, 12 out of 19 patients 
(63.16%) with decreased HDL and 7 out of 12 patients with 
raised LDL had associated impaired glucose metabolism.   
 
  Thus more than 50% of patients with any one form of 
dyslipidemia had associated abnormal glyaemic metabolism 
(Table 6) 
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  The  prevalence of dyslipidemia in female patients 
(65%) was more than in males (46.67%).Totally 54% of 
patients with essential hypertension  had some form of 
dyslipidemia (Table 7) (Fig 5). Previous study by Joglekar 
and Nanivadekar 27 and Malhotra et al28    in India had 
shown similar results.Studies from western countries also 
show29,30,32     similar prevalence. 
 
  24 out of 50 patients (48%) fulfilled the  criteria for 
metabolic syndrome.The prevalence of metabolic syndrome 
in this study was 48% and studies in the Western countries 
31,32       show similar prevalence. 
 
  The prevalence of metabolic syndrome increases with 
age, as does the incidence of diabetes.  Metabolic syndrome 
is strongly  predictive of future diabetes and vascular 
complications.  The high incidence of abnormal glycaemic 
metabolism in hypertensive patients signals the need to 
perform an Oral glucose tolerance test in them.33   Thus we 
can aim at halting vascular impairment in hypertensives 
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with type 2 DM and delay the development of type 2 
diabetes in patients with glucose intolerance. 
  Though physical activity is higher among rural 
population, they have increased prevalence of smoking and 
the Indian diet is rich in carbohydrate.  The urban 
population consumes high fat diet which increases the LDL-
C levels. Other confounding factors for dyslipidemia like 
smoking and alcohol consumption were not included in the 
study.  The common causes of low HDL-C are carbohydrate 
rich diet, smoking, sedentary activity. 
 
  The proposed mechanism of these lipid abnormalities 
are likely to be due to hyperinsulinemia.  Syndrome X  is 
known to predispose hypertensive individuals to higher risk 
of coronary artery disease.34 
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CONCLUSION 
 
1. Prevalence of  previously undiagnosed impaired 
glucose metabolism in patients with essential 
hypertension is 42%. Hence OGTT should be done for 
all patients with essential hypertension. 
2. Prevalence of type 2 diabetes is 10% and impaired 
glucose tolerance is 32%.  
3. Abnormal glycaemic metabolism is more prevalent in  
patients older than 50 years of age. 
4. Abnormal glycaemic metabolism is more common  in 
females 35% . 
5. Prevalence of dyslipidemia  in hypertensive patients is 
54%. 
6. Dyslipidemia is more common in females (65%). 
7. Prevalence of metabolic syndrome in the study group is 
48%. 
8. Impaired glucose metabolism  and dyslipidemia are 
associated with hypertension. 
 
49 
 
 
 
RECOMMENDATIONS AND PREVENTIVE 
ASPECTS35 
 
1. Smoking cessation is the single –most important 
lifestyle modification in all patients with 
hypertension. 
2. Patients should be encouraged to adopt Dietary 
Approaches to stop Hypertension DASH eating plan 
– diet rich in plant food, moderate amounts of meat, 
poultry, fish and low total fat and poly and 
monounsaturated fats.  It is rich in potassium and 
calcium content35. 
3. Salt reduction reduces BP by 5 –7mm Hg when 
sodium intake is reduced below 100 mmol/day (2.4g 
of sodium)36,37 
4. Regular physical activity lowers systolic and 
diastolic BP.  30-45 minutes of moderate aerobic 
exercise per day, is recommended for most days of 
the week.  Yoga and meditation also reduces BP. 
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Life style interventions for BP reduction 
 
Intervention Recommendation Expected 
systolic BP 
reduction 
(range) 
Weight 
reduction 
Maintain ideal BMS 
(20-25 kg/m2) for 
adults 
5-10 mm Hg per 
10kg weight loss 
DASH eating 
plan 
Consume diet atleast 
five portions a day rich 
in fruits vegetables, 
low-fat dairy products 
with reduced content 
of saturated and total 
fat 
8-14 mm Hg 
Physical activity Engage in regular 
aerobic physical 
activity, for example 
brisk walking for at 
least 30 min most 
days a week 
4-9 mm Hg 
Alcohol 
moderation 
Men ≤21 U/week   
Women ≤14 U/week 
2-4mm Hg 
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 Obesity is the driving force behind metabolic 
syndrome.  Thus weight reduction and physical activity are 
very important in increasing insulin sensitivity. 
 
 Early detection of impaired glucose metabolism and  
dyslipidemia, and proper institution of life style 
modifications and pharmacological therapy decrease the 
morbidity and mortality in patients with essential 
hypertension. 
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SUMMARY 
 
 
  The prevalence of undiagnosed impaired glucose 
metabolism is 42% among patients with essential 
hypertension ,and hence oral glucose tolerance test should 
be done in all patients with essential hypertension.The 
prevalence of dyslipidemia in hypertensive patients is 54%.  
Dyslipidemia and metabolic syndrome are common in 
hypertensive patients. 
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S.No Name  Age Sex BPmmHg 
Waist 
circumference 
(CM) 
Blood 
glucose 
fasting mg% 
Glucose 2hr 
post 
prandial 
(mg%) Lipid profile  (mg%) IGT/DM
Dys 
lipidemia
Metabolic 
syndrome 
                TC TG HDL LDL       
1  Subbiah 36 M 160/90 93 65 110 125 78 46 94 - - - 
2  Annalakshmi 56 F 150/100 90 135 162 195 120 47 124 IFG - + 
3  Arunachalam 55 M 180/100 96 75 160 211 101 55 136 IGT  + - 
4  Guruvammal 45 F 170/90 95 98 115 214 176 43 136 - + + 
5  Muthusamy 57 M 160/100 103 135 210 192 129 36 97 DM + + 
6  Mari 46 M 160/96 94 83 132 162 192 40 84 - + - 
7  Tamilselvi 52 F 150/90 90 90 134 185 334 37 92 - + + 
8  Stephen 49 M 140/90 96 93 101 145 125 48 62 - - - 
9  Mymoon 48 F 140/90 95 128 206 191 243 41 91 DM + + 
10  Thangaraj 42 M 150/94 93 93 129 214 196 34 131 - + + 
11  Karuppasamy 55 M 170/100 91 76 130 165 130 40 68 - - - 
12  Vasuki 45 F 146/94 95 110 162 177 161 45 100 IGT + + 
13  Rajadurai 54 M 150/94 104 84 114 142 127 51 86 - - - 
14  Thanraj 69 M 164/90 88 90 103 185 144 50 106 - - - 
15  Mani 55 M 170/90 95 147 188 222 158 42 148 DM + + 
16  Kunaseelan 47 M 146/96 103 82 124 163 128 43 94 - - - 
17  Vaiyali 48 M 150/90 104 129 105 161 113 45 103 IGT - + 
18  Mariappan 49 M 146/90 89 209 310 241 187 38 166 DM + + 
19  Malayandi 58 M 190/120 92 96 162 186 132 42 118 IGT - - 
20  Thilagavathi 55 F 150/80 89 75 103 151 111 50 79 - - - 
21  Kamala 52 F 190/110 93 160 192 229 162 44 153 IGT + + 
22  Thangam 56 F 150/90 91 142 204 186 182 53 98 DM + + 
23  Saraswathi 48 F 180/90 92 84 214 172 126 51 96 IGT - + 
24  Bakkirmydeen 55 M 168/92 98 96 137 157 144 40 88 - - - 
25  Velpandi 45 M 150/96 91 81 122 142 126 48 69 - - - 
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S.No Name  Age Sex BPmmHg 
Waist 
circumference 
(CM) 
Blood 
glucose 
fasting 
mg% 
Glucose 2hr 
post 
prandial 
(mg%)          Lipid profile  (mg%) IGT/DM
Dys 
lipidemia
Metabolic 
syndrome 
                TC TG HDL LDL       
26  Tamilselvi 52 F 150/96 92 134 190 192 134 50 115 IGT - + 
27  Jeyalakshmi 57 F 170/100 90 95 197 225 232 37 142 IGT + -
28  Madhiyarasi 46 F 160/90 91 72 109 186 149 50 106 - - - 
29  John 51 M 146/96 89 84 136 152 120 35 93 - + - 
30  Murugan 37 M 160/92 93 95 166 245 146 38 178 IGT + + 
31  Mangalam 43 F 150/100 89 78 102 136 112 42 72 - - + 
32  Subbu 47 F 170/96 91 84 121 162 146 51 82 - - - 
33  Kathiresan 36 M 144/90 98 120 169 140 121 48 68 IGT - - 
34  Janaki 47 F 146/90 96 121 205 190 238 41 94 IGT + + 
35  Muniraj 38 M 150/90 86 90 126 140 123 40 75 - - - 
36  Megalai 41 F 166/92 93 98 132 156 142 52 76 - - - 
37  Daniel 53 M 176/92 97 132 186 235 210 34 159 IGT + + 
38  Nagarajan 34 M 170/90 95 77 136 149 127 42 82 - - - 
39  Muniyandi 61 M 180/100 96 118 179 184 146 35 120 IGT - + 
40  Subramani 51 M 156/90 90 89 123 191 245 43 99 - + - 
41  Chellapandi 39 M 160/94 103 93 131 179 148 46 105 - - - 
42  Stella 38 F 150/90 91 86 124 242 207 51 150 - + + 
43  Kathija 55 F 160/90 92 82 136 153 122 53 76 - - - 
44  Abdullah 59 M 156/92 94 98 128 178 144 39 110 - + - 
45  Venkatesan 44 M 150/90 96 128 156 237 149 37 170 IGT + + 
46  Arputham 51 F 170/98 93 90 132 287 223 52 171 - + + 
47  Sadagopan 34 M 160/100 96 82 115 156 138 54 95 - - - 
48  Saravanan 62 M 180/100 97 126 177 99 150 41 128 IGT + + 
49  Meenatchi 66 F 166/92 86 76 136 257 215 46 173 - + + 
50  Mayilraj 42 M 158/94 95 88 131 262 221 42 182 - + - 
PATHOGENESIS OF METABOLIC SYNDROME 
 
 
 
 
(FFA-Free fatty acid) 
 
  
FACTORS CONTROLLING BLOOD PRESSURE 
 
 
Excess    Reduced   Stress   Genetic  Obesity         Endothelium 
sodium    nephron     alteration                 derived 
intake    number                        factors 
 
 
          Renal  Decreased  sympathetic  Renin   Cell       Hyper- 
         sodium filteration  nervous over angiotensin  membrane       insulinemia 
        retention surface  activity  excess  alteration   
 
 Fluid   Venous 
 Volume   constriction 
 
  
 Preload   Contractability  Functional     Structural 
         Constriction     hypertrophy 
 
 
BLOOD PRESSURE = CARDIAC OUTPUT  X  PERIPHERAL RESISTANCE 
  Hypertension      =     increased CO      and / or        Increased PR 
 
       Autoregulation     
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PREVALENCE OF  LIPID AND GLYCAEMIC ABNORMALITIES IN 
PATIENTS WITH  ESSENTIAL HYPERTENSION   
 
PROFORMA 
 
Name:                                                      No: 
Age/Sex: 
HISTORY: 
       Hypertension   :                                   CAHD            :                
CVA: 
       Diabetes           :                                   Renal disease: 
EXAMINATION: 
 Pulse:                        Weight:                  Height:                Waist 
circumference: 
 BP: 
 CVS:                        Abdomen: 
 RS:                           CNS:   
Fundus: 
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INVESTIGATIONS: 
Blood:       TC :                         Hb%: 
                  DC:                         ESR: 
Urine:        Albumin- 
                  Sugar     - 
                  Deposit  - 
Blood: Glucose:                 Fasting-                              Urea:    
                          2 Hr Postprandial-                               Creatinine: 
 
LIPID PROFILE: 
Total Cholesterol : 
Triglyceride         : 
            HDL         : 
            LDL         : 
          VLDL        :             
REMARKS     
Impaired glucose tolerance    
Dyslipidemia 
Metabolic syndrome           
